Natixis Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$7.01M Buy
453,527
+33,249
+8% +$514K 0.01% 737
2025
Q1
$6.25M Sell
420,278
-58,301
-12% -$867K 0.01% 759
2024
Q4
$6.34M Buy
478,579
+21,539
+5% +$285K 0.01% 762
2024
Q3
$6.5M Sell
457,040
-11,071
-2% -$157K 0.01% 767
2024
Q2
$6.06M Sell
468,111
-214,178
-31% -$2.77M 0.01% 748
2024
Q1
$9.48M Buy
682,289
+26,185
+4% +$364K 0.02% 625
2023
Q4
$9.36M Sell
656,104
-15,783
-2% -$225K 0.02% 573
2023
Q3
$10.4M Buy
671,887
+10,857
+2% +$168K 0.03% 499
2023
Q2
$10.4M Sell
661,030
-29,398
-4% -$462K 0.03% 515
2023
Q1
$11.4M Sell
690,428
-26,061
-4% -$429K 0.04% 455
2022
Q4
$11.2M Sell
716,489
-50,954
-7% -$795K 0.04% 444
2022
Q3
$9.95M Buy
767,443
+149,114
+24% +$1.93M 0.04% 434
2022
Q2
$8.68M Buy
618,329
+6,920
+1% +$97.2K 0.04% 473
2022
Q1
$8.76M Buy
611,409
+207,871
+52% +$2.98M 0.03% 502
2021
Q4
$5.5M Sell
403,538
-166,334
-29% -$2.27M 0.02% 634
2021
Q3
$9.33M Buy
569,872
+43,941
+8% +$720K 0.04% 446
2021
Q2
$8.85M Buy
525,931
+13,455
+3% +$226K 0.04% 436
2021
Q1
$9.36M Buy
512,476
+192,940
+60% +$3.52M 0.05% 408
2020
Q4
$5.82M Buy
319,536
+36,031
+13% +$656K 0.03% 499
2020
Q3
$5.06M Buy
283,505
+16,394
+6% +$292K 0.03% 519
2020
Q2
$4.79M Sell
267,111
-6,126
-2% -$110K 0.03% 530
2020
Q1
$4.15M Buy
273,237
+61,589
+29% +$935K 0.03% 511
2019
Q4
$4.18M Buy
211,648
+24,083
+13% +$475K 0.03% 596
2019
Q3
$3.23M Buy
187,565
+46,118
+33% +$793K 0.03% 642
2019
Q2
$2.5M Sell
141,447
-2,277
-2% -$40.3K 0.02% 707
2019
Q1
$2.93M Buy
143,724
+57,798
+67% +$1.18M 0.03% 628
2018
Q4
$1.45M Buy
+85,926
New +$1.45M 0.01% 803